J
Julie R. Brahmer
Researcher at Johns Hopkins University School of Medicine
Publications - 39
Citations - 4750
Julie R. Brahmer is an academic researcher from Johns Hopkins University School of Medicine. The author has contributed to research in topics: Lung cancer & Nivolumab. The author has an hindex of 17, co-authored 37 publications receiving 3740 citations.
Papers
More filters
Journal ArticleDOI
Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Julie R. Brahmer,Charles G. Drake,Ira Wollner,John D. Powderly,Joel Picus,William H. Sharfman,Elizabeth Stankevich,Alice Pons,Theresa M. Salay,Tracee L. McMiller,Marta M. Gilson,Changyu Wang,Mark J. Selby,Janis M. Taube,Robert A. Anders,Lieping Chen,Alan J. Korman,Drew M. Pardoll,Israel Lowy,Suzanne L. Topalian +19 more
TL;DR: Blocking the PD-1 immune checkpoint with intermittent antibody dosing is well tolerated and associated with evidence of antitumor activity, and tumor cell surface B7-H1 expression appeared to correlate with the likelihood of response to treatment.
Journal ArticleDOI
Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer
Valsamo Anagnostou,Kellie N. Smith,Patrick M. Forde,Noushin Niknafs,Rohit Bhattacharya,James R. White,Theresa Zhang,Vilmos Adleff,Jillian Phallen,Neha Wali,Carolyn Hruban,Violeta Beleva Guthrie,Kristen Rodgers,Jarushka Naidoo,Hyunseok Kang,William H. Sharfman,Christos S. Georgiades,Franco Verde,Peter B. Illei,Qing Kay Li,Edward Gabrielson,Malcolm V. Brock,Cynthia A. Zahnow,Stephen B. Baylin,Robert B. Scharpf,Julie R. Brahmer,Rachel Karchin,Drew M. Pardoll,Victor E. Velculescu +28 more
TL;DR: This work demonstrates for the first time that acquired resistance to immune checkpoint blockade can arise in association with the evolving landscape of mutations, some of which encode tumor neoantigens recognizable by T cells.
Journal ArticleDOI
Dynamics of tumor and immune responses during immune checkpoint blockade in non–small cell lung cancer
Valsamo Anagnostou,Patrick M. Forde,James R. White,Noushin Niknafs,Carolyn Hruban,Jarushka Naidoo,Kristen A. Marrone,I K Ashok Sivakumar,I K Ashok Sivakumar,I K Ashok Sivakumar,Daniel C. Bruhm,Samuel Rosner,Jillian Phallen,Alessandro Leal,Vilmos Adleff,Kellie N. Smith,Tricia R. Cottrell,Lamia Rhymee,Doreen N. Palsgrove,Christine L. Hann,Benjamin Levy,Josephine Feliciano,Christos S. Georgiades,Franco Verde,Peter B. Illei,Qing Kay Li,Edward Gabrielson,Malcolm V. Brock,James M. Isbell,Jennifer L. Sauter,Janis M. Taube,Robert B. Scharpf,Rachel Karchin,Rachel Karchin,Drew M. Pardoll,Jamie E. Chaft,Matthew D. Hellmann,Julie R. Brahmer,Victor E. Velculescu,Victor E. Velculescu +39 more
TL;DR: Zou et al. as discussed by the authors reported that ultrasound measures of circulating tumor DNA (ctDNA) and T-cell expansion can be used to assess responses to immune checkpoint blockade in metastatic lung cancer patients.
Journal ArticleDOI
The Effect of Preservative and Temperature on the Analysis of Circulating Tumor DNA.
Sonya Parpart-Li,Bjarne Bartlett,Bjarne Bartlett,Maria Popoli,Maria Popoli,Vilmos Adleff,Laura Tucker,Rebecca Steinberg,Andrew Georgiadis,Jillian Phallen,Julie R. Brahmer,Nilofer A Azad,Ilene Browner,Daniel A. Laheru,Victor E. Velculescu,Mark Sausen,Luis A. Diaz,Luis A. Diaz +17 more
TL;DR: Methods of blood processing have a strong influence on cfDNA and ct DNA levels and should be a consideration when evaluating ctDNA in peripheral circulation.
Journal ArticleDOI
Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer
Valsamo Anagnostou,Noushin Niknafs,Kristen A. Marrone,Daniel C. Bruhm,James R. White,Jarushka Naidoo,Karlijn Hummelink,Kim Monkhorst,Ferry Lalezari,Mara Lanis,Samuel Rosner,Joshua E. Reuss,Kellie N. Smith,Vilmos Adleff,Kristen Rodgers,Zineb Belcaid,Lamia Rhymee,Benjamin Levy,Josephine Feliciano,Christine L. Hann,David S. Ettinger,Christos S. Georgiades,Franco Verde,Peter B. Illei,Qing Kay Li,Alexander S. Baras,Edward Gabrielson,Malcolm V. Brock,Rachel Karchin,Rachel Karchin,Drew M. Pardoll,Stephen B. Baylin,Julie R. Brahmer,Robert B. Scharpf,Patrick M. Forde,Victor E. Velculescu +35 more
TL;DR: A new method to estimate a corrected TMB (cTMB) that was adjusted for tumor purity and more accurately predicted outcome to immune checkpoint blockade (ICB) was developed and independently validated.